EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A

Flora Peyvandi, Isabella Garagiola, Cristina Novembrino, Lucia Schiavone, Massimo Boscolo-Anzoletti, Alessandro Ciavarella, Vincenzo La Mura

Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2836-2841

DOI: 10.1016/j.jtha.2026.04.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Flora Peyvandi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, …. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Dependovirus, Genetic Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Università degli Studi di Milano, Ministero dell’Istruzione, dell’Università e della Ricerca, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gene therapy for hemophilia A with valoctocogene roxaparvovec, an adeno-associated virus (AAV) vector encoding B-domain-deleted factor (F)VIII, enables sustained endogenous FVIII expression and long-term bleed protection. FVIII activity is commonly measured using a one-stage clotting assay (OSA) or a chromogenic assay (CA), which yield discrepant results. Data on FVIII transgene expression, assessed by antigen measurements after gene therapy in humans, remain limited. OBJECTIVE: To evaluate the correlation between FVIII activity assessed by OSA and CA and FVIII antigen levels after valoctocogene roxaparvovec administration. METHODS: Four adult patients with severe hemophilia A received a single infusion of valoctocogene roxaparvovec (6 × 1013 vg/kg). FVIII activity was measured by OSA and CA methods; FVIII antigen was quantified using an enzyme-linked immunosorbent assay optimized for B-domain-deleted FVIII. A total of 182 plasma samples were collected at multiple time points post-AAV5 FVIII dosing. RESULTS: The median follow-up time for patients was 61 weeks (IQR, 52.5-115.7). The OSA consistently showed FVIII activity 1.6- to 2-fold higher than the CA, consistent with observations from previous clinical trials. Transgenic FVIII antigen levels positively correlated with FVIII activity measured by the CA, indicating effective transcription and translation of the FVIII transgene. CONCLUSION: FVIII antigen levels showed strong concordance with CA results following AAV-mediated gene therapy. These findings support the CA as the preferred method for monitoring therapeutic FVIII expression in patients treated with gene therapy for hemophilia A. Multiassay strategies remain essential for comprehensive assessment of transgene expression and clinical management after gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIDependovirusGenetic TherapyHumansAdultGenetic VectorsGene Therapy AgentsMaleBlood Coagulation TestsEnzyme-Linked Immunosorbent AssayTreatment OutcomeMiddle AgedBlood CoagulationTime FactorsTransgenes

Stichwörter der Autor:innen

blood coagulation testsfactor VIIIgenetic therapyhemophilia A

Substanzen

Factor VIIIF8 protein, human

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy; Department of Pathophysiology and Transplantation, Università d…
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.

Förderung

  • Università degli Studi di Milano
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Ministero della Salute

Zitieren

APA

Peyvandi, F., Garagiola, I., Novembrino, C., Schiavone, L., Boscolo-Anzoletti, M., Ciavarella, A., & La Mura, V. (2026). Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A. Journal of Thrombosis and Haemostasis, 24(8), 2836-2841. https://doi.org/10.1016/j.jtha.2026.04.017

Vancouver

Peyvandi F, Garagiola I, Novembrino C, Schiavone L, Boscolo-Anzoletti M, Ciavarella A, et al. Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A. Journal of Thrombosis and Haemostasis. 2026;24(8):2836-2841. doi:10.1016/j.jtha.2026.04.017

BibTeX
@article{Peyvandi2026,
  author = {Peyvandi, Flora and Garagiola, Isabella and Novembrino, Cristina and Schiavone, Lucia and Boscolo-Anzoletti, Massimo and Ciavarella, Alessandro and La Mura, Vincenzo},
  title = {Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {8},
  pages = {2836--2841},
  doi = {10.1016/j.jtha.2026.04.017}
}
Kostenlos starten →